← SynDRA
RIMEGEPANT
SynDRA canonical compound SYN0034162 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | CALCA |
|---|
| Mechanism of action | Calcitonin antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Calcitonin antagonist
- CALCRL ANTAGONIST
- Calcitonin gene-related peptide type 1 receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRB2
- ADGRF1
- FPR2
- SMUG1
- S1PR1
- OGG1
- NTHL1
- NEIL2
- NEIL1
- MUTYH
- KCNH2
- HDAC6
- GPR35
- GPR119
- GLP1R
- FFAR4
- ADRA2A
- CYP3A4
- CYP2E1
- CYP2D6
- CYP2C9
- CYP2C19
- CYP2B6
- CYP2A6
- CYP1A2
- CX3CR1
- C5AR1
- APLNR
- AGTR1
- TDG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Calcitonin Gene-related Peptide Receptor Antagonist
- Calcitonin Gene-related Peptide Receptor Antagonists
ATC classes
- N02C · ANTIMIGRAINE PREPARATIONS
Cross-references
Synonyms
- NURTEC ODT
- rimegepant sulfate
- BMS-927711
- nurtec odt
- BHV-3000
- vydura
- Bhv-3000
- BMS 927711
- UNII-997WVV895X
- CHEMBL2178422
- 997WVV895X
- Rimegepant [USAN:INN]
- Rimegepant (USAN/INN)
- SCHEMBL1670580
- DTXSID70156003
- C28H28F2N6O3
- EX-A1922
- 3504AH
- ZINC68267814
- BDBM50400098
- AKOS030526382
- DB12457
- CS-1027
- NCGC00378677-01
- HY-15498
- KB-145921
- W-5991
- rimegepantum
- RefChem:57235
- DTXCID1078494
- Vydura
- BMS927711
- RIMEGEPANT [MI]
- RIMEGEPANT [INN]
- RIMEGEPANT [USAN]
- RIMEGEPANT [WHO-DD]
- BMS-927711(Rimegepant)
- orb1302712
Reported adverse events
- Hypersensitivity
- Hypertension
Look up RIMEGEPANT in the interactive SynDRA portal →